RU2017120481A - Антисмысловые олигонуклеотиды в качестве ингибиторов сигнального пути tgf-r - Google Patents
Антисмысловые олигонуклеотиды в качестве ингибиторов сигнального пути tgf-r Download PDFInfo
- Publication number
- RU2017120481A RU2017120481A RU2017120481A RU2017120481A RU2017120481A RU 2017120481 A RU2017120481 A RU 2017120481A RU 2017120481 A RU2017120481 A RU 2017120481A RU 2017120481 A RU2017120481 A RU 2017120481A RU 2017120481 A RU2017120481 A RU 2017120481A
- Authority
- RU
- Russia
- Prior art keywords
- stb
- sab
- b1sc
- sgb
- sdc
- Prior art date
Links
- 239000000074 antisense oligonucleotide Substances 0.000 title claims 24
- 238000012230 antisense oligonucleotides Methods 0.000 title claims 24
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title claims 2
- 239000003112 inhibitor Substances 0.000 title 1
- 101150025902 SDC gene Proteins 0.000 claims 53
- 108091034117 Oligonucleotide Proteins 0.000 claims 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 206010012289 Dementia Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- -1 7-deazaxanthin Chemical compound 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 108020004999 messenger RNA Proteins 0.000 claims 4
- 101100503760 Deinococcus radiodurans (strain ATCC 13939 / DSM 20539 / JCM 16871 / LMG 4051 / NBRC 15346 / NCIMB 9279 / R1 / VKM B-1422) ssdA gene Proteins 0.000 claims 3
- 206010021143 Hypoxia Diseases 0.000 claims 3
- 230000007850 degeneration Effects 0.000 claims 3
- 206010014599 encephalitis Diseases 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 201000011475 meningoencephalitis Diseases 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000008733 trauma Effects 0.000 claims 3
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 claims 2
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 claims 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 claims 2
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 claims 2
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 claims 2
- PNWOYKVCNDZOLS-UHFFFAOYSA-N 6-amino-5-chloro-1h-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1Cl PNWOYKVCNDZOLS-UHFFFAOYSA-N 0.000 claims 2
- UFVWJVAMULFOMC-UHFFFAOYSA-N 6-amino-5-iodo-1h-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1I UFVWJVAMULFOMC-UHFFFAOYSA-N 0.000 claims 2
- HCGHYQLFMPXSDU-UHFFFAOYSA-N 7-methyladenine Chemical compound C1=NC(N)=C2N(C)C=NC2=N1 HCGHYQLFMPXSDU-UHFFFAOYSA-N 0.000 claims 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical group OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims 2
- 230000001146 hypoxic effect Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
- 229940035893 uracil Drugs 0.000 claims 2
- UHUHBFMZVCOEOV-UHFFFAOYSA-N 1h-imidazo[4,5-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1N=CN2 UHUHBFMZVCOEOV-UHFFFAOYSA-N 0.000 claims 1
- WYDKPTZGVLTYPG-UHFFFAOYSA-N 2,8-diamino-3,7-dihydropurin-6-one Chemical compound N1C(N)=NC(=O)C2=C1N=C(N)N2 WYDKPTZGVLTYPG-UHFFFAOYSA-N 0.000 claims 1
- HTOVHZGIBCAAJU-UHFFFAOYSA-N 2-amino-2-propyl-1h-purin-6-one Chemical compound CCCC1(N)NC(=O)C2=NC=NC2=N1 HTOVHZGIBCAAJU-UHFFFAOYSA-N 0.000 claims 1
- CRYCZDRIXVHNQB-UHFFFAOYSA-N 2-amino-8-bromo-3,7-dihydropurin-6-one Chemical compound N1C(N)=NC(=O)C2=C1N=C(Br)N2 CRYCZDRIXVHNQB-UHFFFAOYSA-N 0.000 claims 1
- YCFWZXAEOXKNHL-UHFFFAOYSA-N 2-amino-8-chloro-3,7-dihydropurin-6-one Chemical compound N1C(N)=NC(=O)C2=C1N=C(Cl)N2 YCFWZXAEOXKNHL-UHFFFAOYSA-N 0.000 claims 1
- GBSSBTKECSBHSE-UHFFFAOYSA-N 2-amino-8-fluoro-3,7-dihydropurin-6-one Chemical compound O=C1NC(N)=NC2=C1NC(F)=N2 GBSSBTKECSBHSE-UHFFFAOYSA-N 0.000 claims 1
- SXGFECRAKVVEJT-UHFFFAOYSA-N 2-amino-8-iodo-3,7-dihydropurin-6-one Chemical compound N1C(N)=NC(=O)C2=C1N=C(I)N2 SXGFECRAKVVEJT-UHFFFAOYSA-N 0.000 claims 1
- USCCECGPGBGFOM-UHFFFAOYSA-N 2-propyl-7h-purin-6-amine Chemical compound CCCC1=NC(N)=C2NC=NC2=N1 USCCECGPGBGFOM-UHFFFAOYSA-N 0.000 claims 1
- LMNPKIOZMGYQIU-UHFFFAOYSA-N 5-(trifluoromethyl)-1h-pyrimidine-2,4-dione Chemical compound FC(F)(F)C1=CNC(=O)NC1=O LMNPKIOZMGYQIU-UHFFFAOYSA-N 0.000 claims 1
- SVXNJCYYMRMXNM-UHFFFAOYSA-N 5-amino-2h-1,2,4-triazin-3-one Chemical compound NC=1C=NNC(=O)N=1 SVXNJCYYMRMXNM-UHFFFAOYSA-N 0.000 claims 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 claims 1
- KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 claims 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 claims 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 claims 1
- KRRQTBVBMPHWQB-UHFFFAOYSA-N 6-amino-1H-pyrimidine-2-thione 5-methyl-2-sulfanylidene-1H-pyrimidin-4-one Chemical compound Nc1ccnc(=S)[nH]1.Cc1c[nH]c(=S)[nH]c1=O KRRQTBVBMPHWQB-UHFFFAOYSA-N 0.000 claims 1
- QFVKLKDEXOWFSL-UHFFFAOYSA-N 6-amino-5-bromo-1h-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1Br QFVKLKDEXOWFSL-UHFFFAOYSA-N 0.000 claims 1
- QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 claims 1
- SSPYSWLZOPCOLO-UHFFFAOYSA-N 6-azauracil Chemical compound O=C1C=NNC(=O)N1 SSPYSWLZOPCOLO-UHFFFAOYSA-N 0.000 claims 1
- AIDIRIDKERNCFT-UHFFFAOYSA-N 6-ethylpurin-6-amine Chemical compound C(C)C1(C2=NC=NC2=NC=N1)N AIDIRIDKERNCFT-UHFFFAOYSA-N 0.000 claims 1
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 claims 1
- CLGFIVUFZRGQRP-UHFFFAOYSA-N 7,8-dihydro-8-oxoguanine Chemical compound O=C1NC(N)=NC2=C1NC(=O)N2 CLGFIVUFZRGQRP-UHFFFAOYSA-N 0.000 claims 1
- LHCPRYRLDOSKHK-UHFFFAOYSA-N 7-deaza-8-aza-adenine Chemical compound NC1=NC=NC2=C1C=NN2 LHCPRYRLDOSKHK-UHFFFAOYSA-N 0.000 claims 1
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 claims 1
- PFUVOLUPRFCPMN-UHFFFAOYSA-N 7h-purine-6,8-diamine Chemical compound C1=NC(N)=C2NC(N)=NC2=N1 PFUVOLUPRFCPMN-UHFFFAOYSA-N 0.000 claims 1
- HRYKDUPGBWLLHO-UHFFFAOYSA-N 8-azaadenine Chemical compound NC1=NC=NC2=NNN=C12 HRYKDUPGBWLLHO-UHFFFAOYSA-N 0.000 claims 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 claims 1
- 229960005508 8-azaguanine Drugs 0.000 claims 1
- FVXHPCVBOXMRJP-UHFFFAOYSA-N 8-bromo-7h-purin-6-amine Chemical compound NC1=NC=NC2=C1NC(Br)=N2 FVXHPCVBOXMRJP-UHFFFAOYSA-N 0.000 claims 1
- XUMSFQKCBNKNCE-UHFFFAOYSA-N 8-iodo-7h-purin-6-amine Chemical compound NC1=NC=NC2=C1NC(I)=N2 XUMSFQKCBNKNCE-UHFFFAOYSA-N 0.000 claims 1
- RGKBRPAAQSHTED-UHFFFAOYSA-N 8-oxoadenine Chemical compound NC1=NC=NC2=C1NC(=O)N2 RGKBRPAAQSHTED-UHFFFAOYSA-N 0.000 claims 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
- 229930024421 Adenine Natural products 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010058029 Arthrofibrosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 208000012239 Developmental disease Diseases 0.000 claims 1
- 208000001708 Dupuytren contracture Diseases 0.000 claims 1
- SUUPRZYDGYNLGW-UHFFFAOYSA-N FC1(N=C2N=CN=C(C2=N1)N)Cl Chemical compound FC1(N=C2N=CN=C(C2=N1)N)Cl SUUPRZYDGYNLGW-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- PJKKQFAEFWCNAQ-UHFFFAOYSA-N N(4)-methylcytosine Chemical compound CNC=1C=CNC(=O)N=1 PJKKQFAEFWCNAQ-UHFFFAOYSA-N 0.000 claims 1
- 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 claims 1
- 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000004362 Penile Induration Diseases 0.000 claims 1
- 208000020758 Peyronie disease Diseases 0.000 claims 1
- 206010036626 Presbyacusis Diseases 0.000 claims 1
- 206010036805 Progressive massive fibrosis Diseases 0.000 claims 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 102000019197 Superoxide Dismutase Human genes 0.000 claims 1
- 108010012715 Superoxide dismutase Proteins 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 206010063661 Vascular encephalopathy Diseases 0.000 claims 1
- 208000035868 Vascular inflammations Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 229960000643 adenine Drugs 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- 231100000895 deafness Toxicity 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 claims 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims 1
- 229960004413 flucytosine Drugs 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 210000000118 neural pathway Anatomy 0.000 claims 1
- 230000010004 neural pathway Effects 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 208000017376 neurovascular disease Diseases 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 208000026881 post-infectious disease Diseases 0.000 claims 1
- 201000010041 presbyopia Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 230000024642 stem cell division Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- 229940113082 thymine Drugs 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 229940075420 xanthine Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/313—Phosphorodithioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
Claims (44)
1. Антисмысловой олигонуклеотид, состоящий из 10-28 нуклеотидов, и, по меньшей мере, два из 10-28 нуклеотидов представляют LNA, и антисмысловой олигонуклеотид способен гибридизоваться с участком гена, кодирующего TGF-RII, или с участком мРНК, кодирующей TGF-RII, где участок гена, кодирующего TGF-RII, или участок мРНК, кодирующей TGF-RII, содержит последовательность TGGTCCATTC (SEQ. ID NO: 4)или последовательность CCCTAAACAC (SEQ. ID NO: 5), или последовательность ACTACCAAAT (SEQ. ID NO: 6), или последовательность GGACGCGTAT (SEQ. ID NO: 7), или последовательность GTCTATGACG (SEQ. ID NO: 8), или последовательность TTATTAATGC (SEQ. ID NO: 9),и антисмысловой олигонуклеотид содержит последовательность, способную гибридизоваться с указанной последовательностью TGGTCCATTC (SEQ. ID NO: 4) или последовательностью CCCTAAACAC (SEQ. ID NO: 5), или последовательностью ACTACCAAAT (SEQ. ID NO: 6), или последовательностью GGACGCGTAT (SEQ. ID NO: 7), или последовательностью GTCTATGACG (SEQ. ID NO: 8), или последовательностью TTATTAATGC (SEQ. ID NO: 9) соответственно, и соли и оптические изомеры указанного антисмыслового олигонуклеотида.
2. Антисмысловой олигонуклеотид по п.1, где антисмысловой олигонуклеотид гибридизуется избирательно только с последовательностью TGGTCCATTC (SEQ. ID NO: 4) или последовательностью CCCTAAACAC (SEQ. ID NO: 5), или последовательностью ACTACCAAAT (SEQ. ID NO: 6), или последовательностью GGACGCGTAT (SEQ. ID NO: 7), или последовательностью GTCTATGACG (SEQ. ID NO: 8), или последовательностью TTATTAATGC (SEQ. ID NO: 9) участка гена, кодирующего TGF-RII, или участка мРНК, кодирующей TGF-RII.
3. Антисмысловой олигонуклеотид по п.1 или 2, где антисмысловой олигонуклеотид имеет длину 12-20 нуклеотидов, и/или где антисмысловой олигонуклеотид имеет гапмерную структуру с 1-5 звеньями LNA на терминальном 3ʹ-конце и 1-5 звеньями LNA на терминальном 5ʹ-конце, и/или где антисмысловой олигонуклеотид содержит фосфат, фосфоротиоат и/или фосфородитиоат в качестве межнуклеотидных связей.
4. Антисмысловой олигонуклеотид по любому из пп.1-3, где антисмысловой олигонуклеотид представлен следующей последовательностью:
5ʹ-N1-GTCATAGA-N2-3ʹ (SEQ. ID NO: 12) или
5ʹ-N3-ACGCGTCC-N4-3ʹ (SEQ. ID NO: 98) или
5ʹ-N5-TTTGGTAG-N6-3ʹ (SEQ. ID NO: 11) или
5ʹ-N 7 -AATGGACC-N 8 -3ʹ (SEQ. ID NO: 100) или
5ʹ-N9-ATTAATAA-N10-3ʹ (SEQ. ID NO: 101) или
5ʹ-N11-TGTTTAGG-N12-3ʹ (SEQ. ID NO: 10) или
где:
N1 представляет: CATGGCAGACCCCGCTGCTC-, ATGGCAGACCCCGCTGCTC-, TGGCAGACCCCGCTGCTC-, GGCAGACCCCGCTGCTC-, GCAGACCCCGCTGCTC-, CAGACCCCGCTGCTC-, AGACCCCGCTGCTC-, GACCCCGCTGCTC-, ACCCCGCTGCTC-, CCCCGCTGCTC-, CCCGCTGCTC-, CCGCTGCTC-, CGCTGCTC-, GCTGCTC-, CTGCTC-, TGCTC-, GCTC-, CTC-, TC- или C-;
N2 представляет: -C, -CC, -CCG, -CCGA, -CCGAG, -CCGAGCC, -CCGAGCCCCC, -CCGAGCCCCCC, -CCGAGCCCCCCAG, -CCGAGCCCCCAGC, -CCGAGCCCCCAGCG, -CCGAGCCCCCAGCGC, -CCGAGCCCCCAGCGCA, -CCGAGCCCCCAGCGCAG, -CCGAGCCCCCAGCGCAGC, -CCGAGCCCCCAGCGCAGCGG или -CCGAGCCCCCAGCGCAGCGG;
N3 представляет: GGTGGGATCGTGCTGGCGAT-, GTGGGATCGTGCTGGCGAT-, TGGGATCGTGCTGGCGAT-, GGGATCGTGCTGGCGAT-, GGATCGTGCTGGCGAT-, GATCGTGCTGGCGAT-, ATCGTGCTGGCGAT-, TCGTGCTGGCGAT-, CGTGCTGGCGAT-, GTGCTGGCGAT-, TGCTGGCGAT-, GCTGGCGAT-, CTGGCGAT-, TGGCGAT-, GGCGAT-, GCGAT-, CGAT-, GAT-, AT- или Т-;
N4 представляет: -ACAGGACGATGTGCAGCGGC, -ACAGGACGATGTGCAGCGG, -ACAGGACGATGTGCAGCG, -ACAGGACGATGTGCAGC, -ACAGGACGATGTGCAG, -ACAGGACGATGTGCA, -ACAGGACGATGTGC, -ACAGGACGATGTG, -ACAGGACGATGT, -ACAGGACGATG, -ACAGGACGAT, -ACAGGACGA, -ACAGGACG, -ACAGGAC, -ACAGGA, -ACAGG, -ACAG, -ACA, -AC или -A;
N5 представляет: GCCCAGCCTGCCCCAGAAGAGCTA-, CCCAGCCTGCCCCAGAAGAGCTA-, CCAGCCTGCCCCAGAAGAGCTA-, CAGCCTGCCCCAGAAGAGCTA-, AGCCTGCCCCAGAAGAGCTA-, GCCTGCCCCAGAAGAGCTA-, CCTGCCCCAGAAGAGCTA-, CTGCCCCAGAAGAGCTA-, TGCCCCAGAAGAGCTA-, GCCCCAGAAGAGCTA-, CCCCAGAAGAGCTA-, CCCAGAAGAGCTA-, CCAGAAGAGCTA-, CAGAAGAGCTA-, AGAAGAGCTA-, GAAGAGCTA-, AAGAGCTA-, AGAGCTA-, GAGCTA-, AGCTA-, GCTA-, CTA-, TA- или A-;
N6 представляет: -TGTTTAGGGAGCCGTCTTCAGGAA, -TGTTTAGGGAGCCGTCTTCAGGA, -TGTTTAGGGAGCCGTCTTCAGG, -TGTTTAGGGAGCCGTCTTCAG, -TGTTTAGGGAGCCGTCTTCA, -TGTTTAGGGAGCCGTCTTC, -TGTTTAGGGAGCCGTCTT, -TGTTTAGGGAGCCGTCT, -TGTTTAGGGAGCCGTC, -TGTTTAGGGAGCCGT, -TGTTTAGGGAGCCG, -TGTTTAGGGAGCC, -TGTTTAGGGAGC, -TGTTTAGGGAG, -TGTTTAGGGA, -TGTTTAGGG, -TGTTTAGG, -TGTTTAG, -TGTTTA, -TGTTT, -TGTT, -TGT, -TG или -T;
N7 представляет: TGAATCTTGAATATCTCATG-, GAATCTTGAATATCTCATG-, AATCTTGAATATCTCATG-, ATCTTGAATATCTCATG-, TCTTGAATATCTCATG-, CTTGAATATCTCATG-, TTGAATATCTCATG-, TGAATATCTCATG-, GAATATCTCATG-, AATATCTCATG-, ATATCTCATG-, TATCTCATG-, ATCTCATG-, TCTCATG-, CTCATG-, TCATG-, CATG-, ATG-, TG- или G-; и
N8 выбран из: -AGTATTCTAGAAACTCACCA, -AGTATTCTAGAAACTCACC, -AGTATTCTAGAAACTCAC, -AGTATTCTAGAAACTCA, -AGTATTCTAGAAACTC, -AGTATTCTAGAAACT, -AGTATTCTAGAAAC, -AGTATTCTAGAAA, -AGTATTCTAGAA, -AGTATTCTAGA, -AGTATTCTAG, -AGTATTCTA, -AGTATTCT, -AGTATTC, -AGTATT, -AGTAT, -AGTA, -AGT, -AG или -A;
N9 представляет: ATTCATATTTATATACAGGC-, TTCATATTTATATACAGGC-, TCATATTTATATACAGGC-, CATATTTATATACAGGC-, ATATTTATATACAGGC-, TATTTATATACAGGC-, ATTTATATACAGGC-, TTTATATACAGGC-, TTATATACAGGC-, TATATACAGGC-, ATATACAGGC-, TATACAGGC-, ATACAGGC-, TACAGGC-, ACAGGC-, CAGGC-, AGGC-, GGC-, GC- или C-;
N10 представляет: -AGTGCAAATGTTATTGGCTA, -AGTGCAAATGTTATTGGCT, -AGTGCAAATGTTATTGGC, -AGTGCAAATGTTATTGG, -AGTGCAAATGTTATTG, -AGTGCAAATGTTATT, -AGTGCAAATGTTAT, -AGTGCAAATGTTA, -AGTGCAAATGTT, -AGTGCAAATGT, -AGTGCAAATG, -AGTGCAAAT, -AGTGCAAA, -AGTGCAA, -AGTGCA, -AGTGC, -AGTG, -AGT, -AG или -A;
N11 представляет: TGCCCCAGAAGAGCTATTTGGTAG-, GCCCCAGAAGAGCTATTTGGTAG-, CCCCAGAAGAGCTATTTGGTAG-, CCCAGAAGAGCTATTTGGTAG-, CCAGAAGAGCTATTTGGTAG-, CAGAAGAGCTATTTGGTAG-, AGAAGAGCTATTTGGTAG-, GAAGAGCTATTTGGTAG-, AAGAGCTATTTGGTAG-, AGAGCTATTTGGTAG-, GAGCTATTTGGTAG-, AGCTATTTGGTAG-, GCTATTTGGTAG-, CTATTTGGTAG-, TATTTGGTAG-, ATTTGGTAG-, TTTGGTAG-, TTGGTAG-, TGGTAG-, GGTAG-, GTAG-, TAG-, AG- или G-,
N12 представляет: -GAGCCGTCTTCAGGAATCTTCTCC, -GAGCCGTCTTCAGGAATCTTCTC, -GAGCCGTCTTCAGGAATCTTCT, -GAGCCGTCTTCAGGAATCTTC, -GAGCCGTCTTCAGGAATCTT, -GAGCCGTCTTCAGGAATCT, -GAGCCGTCTTCAGGAATC,-GAGCCGTCTTCAGGAAT, -GAGCCGTCTTCAGGAA, -GAGCCGTCTTCAGGA,-GAGCCGTCTTCAGG, -GAGCCGTCTTCAG, -GAGCCGTCTTCA, -GAGCCGTCTTC, -GAGCCGTCTT, -GAGCCGTCT, -GAGCCGTC, -GAGCCGT,-GAGCCG, -GAGCC, -GAGC, -GAG, -GA или -G.
5. Антисмысловой олигонуклеотид по любому из пп.1-4, где последние 2-4 нуклеотида на терминальном 5ʹ-конце представляют нуклеотиды LNA, и последние 2-4 нуклеотида на терминальном 3ʹ-конце представляют нуклеотиды LNA, и между нуклеотидами LNA на терминальном 5ʹ-конце и нуклеотидами LNA на терминальном 3ʹ-конце находится, по меньшей мере, 6 последовательных нуклеотидов, представляющих нуклеотиды, которые не являются LNA, или которые представляют нуклеотиды ДНК.
6. Антисмысловой олигонуклеотид по любому из пп.1-5, где нуклеотиды LNA связаны друг с другом через фосфоротиоатную группу или фосфородитиоатную группу, или где все нуклеотиды связаны друг с другом через фосфатную группу или фосфоротиоатную группу, или фосфородитиоатную группу.
7. Антисмысловой олигонуклеотид по любому из пп.1-6, где нуклеотиды LNA выбраны из следующей группы:
где:
ILʹ представляет -Xʺ-P(=Xʹ)(X-)-;
Xʹ представляет =O или =S;
X- представляет -O-, -OH, -ORH, -NHRH, -N(RH)2, -OCH2CH2ORH, -OCH2CH2SRH, -BH3 -, -RH, -SH, -SRH или -S-;
Xʺ представляет -O-, -NH-, -NRH-, -CH2- или –S-;
Y представляет -O-, -NH-, -NRH-, -CH2- или –S-;
RC и RH независимо друг от друг выбраны из атома водорода и C1-4-алкила.
В представляет азотистое основание, выбранное из следующей группы:
аденин, тимин, гуанин, цитозин, урацил, 5-метилцитозин, 5-гидроксиметилцитозин, N4-метилцитозин, ксантин, гипоксантин, 7-деазаксантин, 2-аминоаденин, 6-метиладенин, 6-метилгуанин, 6-этиладенин, 6-этилгуанин, 2-пропиладенин, 2-пропилгуанин, 6-карбоксиурацил, 5,6-дигидроурацил, 5-пропинилурацил, 5-пропинилцитозин, 6-азаурацил, 6-азацитозин, 6-азатимин, 5-урацил, 4-тиоурацил, 8-фтораденин, 8-хлораденин, 8-бромаденин, 8-иодаденин, 8-аминоаденин, 8-тиоладенин, 8-тиоалкиладенин, 8-гидроксиладенин, 8-фторгуанин, 8-хлоргуанин, 8-бромгуанин, 8-иодгуанин, 8-аминогуанин, 8-тиолгуанин, 8-тиоалкилгуанин, 8-гидроксилгуанин, 5-фторурацил, 5-бромурацил, 5-хлорурацил, 5-иодурацил, 5-трифторметилурацил, 5-фторцитозин, 5-бромцитозин, 5-хлорцитозин, 5-иодцитозин, 5-трифторметилцитозин, 7-метилгуанин, 7-метиладенин, 8-азагуанин, 8-азааденин, 7-деазагуанин, 7-деазааденин, 7-деаза-8-азааденин, 3-деазагуанин, 3-деазааденин, 2-тиоурацил, 2-тиотимин и 2-тиоцитозин.
8. Антисмысловой олигонуклеотид по любому из пп.1-7, имеющий одну из следующих гапмерных структур: 3-8-3, 4-8-2, 2-8-4, 3-8-4, 4-8-3, 4-8-4, 3-9-3, 4-9-2, 2-9-4, 4-9-3, 3-9-4, 4-9-4, 3-10-3, 2-10-4, 4-10-2, 3-10-4, 4-10-3, 4-10-4, 2-11-4, 4-11-2, 3-11-4, 4-11-3.
9. Антисмысловой олигонуклеотид по любому из пп.1-8, где антисмысловые олигонуклеотиды связываются со 100% комплементарностью с мРНК, кодирующей TGF-RII, и не связываются с каким-либо другим участком в транскриптоме человека.
10. Антисмысловой олигонуклеотид, выбранный из следующей группы:
11. Антисмысловой олигонуклеотид по любому из пп.1-10 для стимуляции регенерации и функционального восстановления поврежденных нервных путей и/или для лечения и компенсации индуцированного возрастом снижения обновления нейрональных стволовых клеток.
12. Антисмысловой олигонуклеотид по любому из пп.1-10 для применения в профилактике и лечении нейродегенеративных заболеваний, нейровоспалительных расстройств, травматических или посттравматических расстройств, нейрососудистых расстройств, гипоксических расстройств, постинфекционных расстройств центральной нервной системы, фиброзных болезней, гиперпролиферативных заболеваний, рака, опухолей, пресбиакузиса и пресбиопии.
13. Антисмысловой олигонуклеотид для применения по п.12, где нейродегенеративные заболевания и нейровоспалительные расстройства выбраны из группы, состоящей из: болезни Альцгеймера, болезни Паркинсона, болезни Крейтцфельдта-Якоба, нового варианта болезни Крейтцфельдта-Якоба, болезни Галлервордена-Шпатца, болезни Гентингтона, мультисистемной атрофии, деменции, лобно-височной деменции, расстройств двигательного нейрона, бокового амиотрофического склероза, спинномозговой мышечной атрофии, спиноцеребеллярных атрофий, шизофрении, аффективных расстройств, большого депрессивного расстройства, менингоэнцефалита, бактериального менингоэнцефалита, вирусного менингоэнцефалита, аутоиммунных расстройств ЦНС, рассеянного склероза, острых ишемических/гипоксических поражений, травмы центральной нервной системы и спинного мозга, травмы головы и позвоночника, черепно-мозговых травм, артериосклероза, атеросклероза, микроангиопатической деменции, болезни Бинсвангера, дегенерации сетчатки, улитковой дегенерации, дегенерации желтого пятна, улитковой глухоты, деменции, связанной со СПИДом, пигментного ретинита, Х-сцепленного рецессивного синдрома тремора/атаксии, прогрессирующего супрануклеарного паралича, стриатонигральной дегенерации, оливопонтомозжечковой дегенерации, синдрома Шая-Дрейджера, зависящего от возраста дефицита памяти, неврологических расстройств развития, связанных с деменцией, синдрома Дауна, синуклеинопатий, мутаций супероксиддисмутазы, расстройств повторов тринуклеотида, травмы, гипоксии, сосудистых заболеваний, сосудистых воспалений и старения ЦНС, и где фиброзные болезни выбраны из группы, состоящей из: фиброза легких, кистозного фиброза, цирроза печени, эндомиокардиального фиброза, «старого» инфаркта миокарда, фиброза предсердий, фиброза средостения, миелофиброза, забрюшинного фиброза, прогрессирующего массивного фиброза, нефрогенного системного фиброза, болезни Крона, келоида, системного склероза, артрофиброза, болезни Пейрони, контрактуры Дюпюитрена и остаточных явлений после красной волчанки.
14. Фармацевтическая композиция, содержащая, по меньшей мере, один антисмысловой олигонуклеотид по любому из пп.1-10 вместе, по меньшей мере, с одним фармацевтически приемлемым носителем, эксципиентом, адъювантом, растворителем или разбавителем.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14193368.9A EP3020813A1 (en) | 2014-11-16 | 2014-11-16 | Antisense-oligonucleotides as inhibitors of TGF-R signaling |
EP14193368.9 | 2014-11-16 | ||
PCT/EP2015/076730 WO2016075339A1 (en) | 2014-11-16 | 2015-11-16 | Antisense-oligonucleotides as inhibitors of tgf-r signaling |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2017120481A true RU2017120481A (ru) | 2018-12-18 |
RU2017120481A3 RU2017120481A3 (ru) | 2019-05-27 |
RU2717454C2 RU2717454C2 (ru) | 2020-03-23 |
Family
ID=51900289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017120481A RU2717454C2 (ru) | 2014-11-16 | 2015-11-16 | Антисмысловые олигонуклеотиды в качестве ингибиторов сигнального пути tgf-r |
Country Status (22)
Country | Link |
---|---|
US (4) | US11213541B2 (ru) |
EP (3) | EP3020813A1 (ru) |
JP (2) | JP6832285B2 (ru) |
KR (2) | KR102310899B1 (ru) |
CN (2) | CN113151261A (ru) |
AU (3) | AU2015345006B2 (ru) |
BR (1) | BR112017006201B1 (ru) |
CA (2) | CA2964834C (ru) |
CL (2) | CL2017001233A1 (ru) |
CY (1) | CY1121110T1 (ru) |
DK (1) | DK3218488T3 (ru) |
ES (1) | ES2705066T3 (ru) |
HU (1) | HUE041793T2 (ru) |
IL (2) | IL251565B (ru) |
MX (2) | MX2017006369A (ru) |
MY (1) | MY181404A (ru) |
PL (1) | PL3218488T3 (ru) |
PT (1) | PT3218488T (ru) |
RU (1) | RU2717454C2 (ru) |
SG (1) | SG11201703127SA (ru) |
TR (1) | TR201900844T4 (ru) |
WO (1) | WO2016075339A1 (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3020813A1 (en) * | 2014-11-16 | 2016-05-18 | Neurovision Pharma GmbH | Antisense-oligonucleotides as inhibitors of TGF-R signaling |
WO2019010226A1 (en) * | 2017-07-03 | 2019-01-10 | The Regents Of The University Of California | CHEMICALLY MODIFIED MICROARN-214 ANTISENS AND USE THEREOF FOR THE TREATMENT OF HEMORRHAGIC RECTOCOLITE AND PROCTITE |
EP4092118A1 (en) * | 2017-12-22 | 2022-11-23 | Roche Innovation Center Copenhagen A/S | Novel thiophosphoramidites |
AU2018386527A1 (en) * | 2017-12-22 | 2020-04-30 | Roche Innovation Center Copenhagen A/S | Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage |
WO2019122279A1 (en) * | 2017-12-22 | 2019-06-27 | Roche Innovation Center Copenhagen A/S | Oligonucleotides comprising a phosphorodithioate internucleoside linkage |
EP4237436A2 (en) * | 2020-10-29 | 2023-09-06 | Mariano A. Garcia-Blanco | Soluble interleukin-7 receptor (sil7r) modulating therapy to treat cancer |
CN114588160A (zh) * | 2020-12-07 | 2022-06-07 | 四川大学华西医院 | 具有抗肺纤维化作用的次黄碱衍生物 |
CN113992687B (zh) * | 2021-12-28 | 2022-04-08 | 浙江宇视科技有限公司 | 智能业务集群调度方法、装置、电子设备及存储介质 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU722735B2 (en) | 1996-02-19 | 2000-08-10 | Nycomed Imaging As | Thermally stabilized contrast agent |
US20030064944A1 (en) * | 2001-06-21 | 2003-04-03 | Isis Pharmaceuticals Inc. | Antisense modulation of transforming growth factor beta receptor II expression |
EP2141233B1 (en) | 2002-11-18 | 2016-10-19 | Roche Innovation Center Copenhagen A/S | Antisense design |
JP2007502284A (ja) * | 2003-08-13 | 2007-02-08 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ | siRNAによるTGFベータII型受容体発現のサイレンシング |
ZA200606460B (en) * | 2004-02-09 | 2008-02-27 | Regenion Gmbh | Inhibitors of TGF-R signaling for treatment of CNS disorders |
WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
WO2007090071A2 (en) | 2006-01-27 | 2007-08-09 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
WO2007112753A2 (en) | 2006-04-03 | 2007-10-11 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
JP5441688B2 (ja) | 2006-05-11 | 2014-03-12 | アイシス ファーマシューティカルズ, インコーポレーテッド | 5’修飾二環式核酸類似体 |
EP2090127A2 (en) | 2006-10-30 | 2009-08-19 | Nokia Corporation | Method, apparatus and system providing operator controlled mobility for user equipment |
WO2008109546A2 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tgfbr gene expression and uses thereof |
ES2388590T3 (es) | 2007-05-30 | 2012-10-16 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos con puente aminometileno N-sustituido. |
DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
CA2692579C (en) | 2007-07-05 | 2016-05-03 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
US8546556B2 (en) | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
CN102089429A (zh) * | 2008-07-15 | 2011-06-08 | 弗·哈夫曼-拉罗切有限公司 | 用于抑制TGF-β受体基因表达的组合物和方法 |
NZ598943A (en) * | 2009-10-16 | 2014-09-26 | Glaxo Group Ltd | Hbv antisense inhibitors |
AU2011263642B2 (en) * | 2010-06-11 | 2014-09-04 | Isarna Therapeutics Gmbh | Method for selective oligonucleotide modification |
US9115371B2 (en) * | 2011-08-18 | 2015-08-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Reduction of TGF beta signaling in myeloid cells in the treatment of cancer |
CN104004762B (zh) * | 2014-05-20 | 2016-03-30 | 南京医科大学附属南京儿童医院 | Tgf-r反义序列及其在制备抗气道炎症反应药物中的应用 |
EP3020813A1 (en) * | 2014-11-16 | 2016-05-18 | Neurovision Pharma GmbH | Antisense-oligonucleotides as inhibitors of TGF-R signaling |
-
2014
- 2014-11-16 EP EP14193368.9A patent/EP3020813A1/en not_active Ceased
-
2015
- 2015-11-16 MY MYPI2017701692A patent/MY181404A/en unknown
- 2015-11-16 EP EP18184873.0A patent/EP3418385A1/en active Pending
- 2015-11-16 BR BR112017006201-1A patent/BR112017006201B1/pt active IP Right Grant
- 2015-11-16 KR KR1020177016366A patent/KR102310899B1/ko active IP Right Grant
- 2015-11-16 CN CN202110048326.1A patent/CN113151261A/zh active Pending
- 2015-11-16 TR TR2019/00844T patent/TR201900844T4/tr unknown
- 2015-11-16 WO PCT/EP2015/076730 patent/WO2016075339A1/en active Application Filing
- 2015-11-16 SG SG11201703127SA patent/SG11201703127SA/en unknown
- 2015-11-16 RU RU2017120481A patent/RU2717454C2/ru active
- 2015-11-16 KR KR1020217028947A patent/KR102417601B1/ko active IP Right Grant
- 2015-11-16 US US15/525,561 patent/US11213541B2/en active Active
- 2015-11-16 PL PL15797640T patent/PL3218488T3/pl unknown
- 2015-11-16 AU AU2015345006A patent/AU2015345006B2/en active Active
- 2015-11-16 ES ES15797640T patent/ES2705066T3/es active Active
- 2015-11-16 HU HUE15797640A patent/HUE041793T2/hu unknown
- 2015-11-16 DK DK15797640.8T patent/DK3218488T3/en active
- 2015-11-16 CA CA2964834A patent/CA2964834C/en active Active
- 2015-11-16 EP EP15797640.8A patent/EP3218488B1/en active Active
- 2015-11-16 CN CN201580056200.1A patent/CN107002082B/zh active Active
- 2015-11-16 JP JP2017544992A patent/JP6832285B2/ja active Active
- 2015-11-16 US US14/942,899 patent/US10363266B2/en active Active
- 2015-11-16 MX MX2017006369A patent/MX2017006369A/es unknown
- 2015-11-16 PT PT15797640T patent/PT3218488T/pt unknown
- 2015-11-16 CA CA3201845A patent/CA3201845C/en active Active
-
2017
- 2017-04-04 IL IL251565A patent/IL251565B/en active IP Right Grant
- 2017-05-15 CL CL2017001233A patent/CL2017001233A1/es unknown
- 2017-05-16 MX MX2020011476A patent/MX2020011476A/es unknown
-
2018
- 2018-12-28 CY CY181101402T patent/CY1121110T1/el unknown
-
2019
- 2019-04-11 CL CL2019000980A patent/CL2019000980A1/es unknown
- 2019-06-14 US US16/442,054 patent/US20190314401A1/en not_active Abandoned
- 2019-09-05 IL IL269151A patent/IL269151B2/en unknown
-
2020
- 2020-10-22 AU AU2020257116A patent/AU2020257116B2/en active Active
- 2020-10-26 AU AU2020260380A patent/AU2020260380B2/en active Active
-
2021
- 2021-02-01 JP JP2021014438A patent/JP6983343B2/ja active Active
- 2021-11-08 US US17/453,950 patent/US20220143071A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2017120481A (ru) | Антисмысловые олигонуклеотиды в качестве ингибиторов сигнального пути tgf-r | |
US20240035032A1 (en) | Oligomers and oligomer conjugates | |
US20160108396A1 (en) | Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene | |
JP6027542B2 (ja) | 非コード免疫調節性dna構築物 | |
CA2866392C (en) | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome | |
JP2022062143A (ja) | 腎臓病の処置のための組成物と方法 | |
US20100215646A1 (en) | Immunostimulatory activity of palindromic immune modulatory oligonucleotides (imo) containing different lengths of palindromic segments | |
EP2920308A1 (en) | Cancer treatment | |
JP2018512127A5 (ru) | ||
CA2578775A1 (en) | Methods and compositions for inhibition of innate immune responses and autoimmunity | |
JP7155302B2 (ja) | Atxn3を標的とするアンチセンスオリゴヌクレオチド | |
US20240150758A1 (en) | Use of fubp1 inhibitors for treating hepatitis b virus infection | |
WO2016019063A1 (en) | Compositions and methods for modulating tau expression | |
US20190345495A1 (en) | Antisense oligonucleotides for modulating nfkb2 expression | |
JP2011505798A (ja) | Mcl−1を調節するためのRNAアンタゴニスト化合物 | |
US20200216845A1 (en) | Antisense oligonucleotides for modulating rela expression | |
CN220699235U (zh) | 一种金刚石树脂布拉磨块 | |
WO2020007889A1 (en) | Antisense oligonucleotides targeting stat1 | |
WO2020007772A1 (en) | Antisense oligonucleotides targeting gbp-1 |